QuidelOrtho Corporation (QDEL)

US — Healthcare Sector
Peers: PODD  GMED  NVCR  BIO  RGEN  FLGT  DXCM  MASI 

Automate Your Wheel Strategy on QDEL

With Tiblio's Option Bot, you can configure your own wheel strategy including QDEL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol QDEL
  • Rev/Share 40.514
  • Book/Share 41.2511
  • PB 0.7139
  • Debt/Equity 1.0
  • CurrentRatio 1.1221
  • ROIC -0.0099

 

  • MktCap 1999668724.0
  • FreeCF/Share 1.8213
  • PFCF 16.2179
  • PE -4.2748
  • Debt/Assets 0.4378
  • DivYield 0
  • ROE -0.156

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade QDEL Jefferies Hold Buy -- $44 May 8, 2025
Upgrade QDEL Citigroup Neutral Buy $44 $50 Dec. 11, 2024
Initiation QDEL Jefferies -- Hold -- $43 Dec. 10, 2024
Resumed QDEL UBS -- Neutral $42 $50 Sept. 19, 2024
Upgrade QDEL Craig Hallum Hold Buy $40 $57 Sept. 5, 2024

News

QuidelOrtho Corporation (QDEL) Q4 2024 Earnings Call Transcript
QDEL
Published: February 12, 2025 by: Seeking Alpha
Sentiment: Neutral

QuidelOrtho Corporation (NASDAQ:QDEL ) Q4 2024 Results Conference Call February 12, 2025 5:00 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Brian Blaser - President and Chief Executive Officer Joe Busky - Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research Patrick Donnelly - Citi Bill Bonello - Craig-Hallum Lu Li - UBS Andrew Cooper - Raymond James Casey Woodring - JPMorgan Andrew Brackmann - William Blair Jose Ricardo - RBC Capital Markets Operator Welcome to the QuidelOrtho Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast. At this time, all participant …

Read More
image for news QuidelOrtho Corporation (QDEL) Q4 2024 Earnings Call Transcript

About QuidelOrtho Corporation (QDEL)

  • IPO Date 1991-02-01
  • Website https://www.quidelortho.com
  • Industry Medical - Instruments & Supplies
  • CEO Brian J. Blaser
  • Employees 6600
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.